The ameliorating effect of the extract of the flower of Prunella vulgaris var. lilacina on drug-induced memory impairments in mice

Park, Se Jin; Kim, Dong Hyun; Lee, Il Kyun; Jung, Won Yong; Park, Dong Hyun; Kim, Jong Min; Lee, Kang Ro; Lee, Kyung Tae; Shin, Chan Young; Cheong, Jae Hoon; Ko, Kwang Ho; Ryu, Jong Hoon

doi:10.1016/j.fct.2010.03.042

Cited by 41 publications

(32 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…vulgaris was obtained from Inno-Pharm (Seoul, Korea). To prepare the ethanolic extract, we performed our previously described method (Park et al, 2010). Briefly, air-dried and powdered aerial parts of the plant were macerated with 70% ethanol (1000 g/10 l) twice at 60 °C in an ultrasonic bath for 2 h. Then, the resultant ethanol solution was filtered, concentrated in a water bath under vacuum using a rotary evaporator.…”

Section: Methodsmentioning

confidence: 99%

Ursolic acid enhances pentobarbital-induced sleeping behaviors via GABAergic neurotransmission in mice

Jeon

Park

Gao

et al. 2015

European Journal of Pharmacology

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Ursolic acid enhances pentobarbital-induced sleeping behaviors via GABAergic neurotransmission in mice

Jeon

Park

Gao

et al. 2015

European Journal of Pharmacology

Self Cite

View full text Add to dashboard Cite

“…These biphasic curves are not assay or domain dependent because they have been described for executive function in an attentional set-shifting paradigm (Jones et al, 2014), working memory (Berridge et al, 2012), spatial memory (Park et al, 2010;Wise and Lichtman, 2007), social investigation (Gacsályi et al, 2013), anxiety (Foreman et al, 2009;Hendrie et al, 1993;Vaidya et al, 2005) and visual memory (Horiguchi et al, 2013;Uslaner et al, 2009), among many others.…”

Section: Dose Selection: the Yerkes-dodson Principlementioning

confidence: 97%

True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence

Goetghebeur

Swartz

2016

J Psychopharmacol

View full text Add to dashboard Cite

Central nervous system pharmacological research and development has reached a critical turning point. Patients suffering from disorders afflicting the central nervous system are numerous and command significant attention from the pharmaceutical industry. However, given the numerous failures of promising drugs, many companies are no longer investing in or, indeed, are divesting from this therapeutic area. Central nervous system drug development must change in order to develop effective therapies to treat these patients. Preclinical research is a cornerstone of drug development; however, it is frequently criticised for its lack of predictive validity. Animal models and assays can be shown to be more predictive than reported and, on many occasions, the lack of thorough preclinical testing is potentially to blame for some of the clinical failures. Important factors such as translational aspects, nature of animal models, variances in acute versus chronic dosing, development of add-on therapies and understanding of the full dose-response relationship are too often neglected. Reducing the attrition rate in central nervous system drug development could be achieved by addressing these important questions before novel compounds enter the clinical phase. This review illustrates the relevance of employing these criteria to translational central nervous system research, better to ensure success in developing new drugs in this therapeutic area.

show abstract

“…lilacina ameliorated drug-induced memory dysfunction (Park et al, 2010) and showed anti-allergic and anti-inflammatory activity (Ryu et al, 2000;Psotová et al, 2003). Previous studies indicated that the Prunella vulgaris var.…”

Section: Discussionmentioning

confidence: 99%

“…lilacina is one of the most widely used medical plants in north-eastern Asian countries and have been used for traditional herbal medicine to treat fever, inflammation, dropsy, gonorrhea and cancer (Park et al, 2010). Although several studies have reported that it has many biological activities (Ryu et al, 2000;Psotová et al, 2003), little is known to regarding its antioxidant properties which is related to these beneficial properties.…”

Section: Introductionmentioning

confidence: 99%

Antioxidant Activity of Different Solvent Fractions from Prunella vulgaris var. lilacina

Park¹,

Park²,

Chon³

et al. 2011

Korean Journal of Medicinal Crop Science

View full text Add to dashboard Cite

The potential antioxidant activities of different fractions from Prunella vulgaris var. lilacina were assayed in vitro. Among several fractions, n-BuOH fraction showed the highest 1,1-di[henyl-2-picrylhydrazyl (DPPH) free radical scavenging (IC 50 = 0.50 ㎍/mL). The results of 2,2'-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) radical scavenging activity and ferric reducing antioxidant power (FRAP) assay showed the concentration dependency and n-BuOH fraction appeared a better result than the other fractions at the same concentration in this study. Moreover the total phenol and flavonoid contents of n-BuOH fraction contained the highest level. Additionally, correlation analysis indicated a high correlation between the antiradical activity and the total phenolic and flavonoid contents (p < 0.001). It suggests that n-BuOH fraction obtained from the 70% EtOH crude extract of Prunella vulgaris var. lilacina has wide potential for use as a source of antioxidant material.

show abstract

The ameliorating effect of the extract of the flower of Prunella vulgaris var. lilacina on drug-induced memory impairments in mice

Cited by 41 publications

References 43 publications

Ursolic acid enhances pentobarbital-induced sleeping behaviors via GABAergic neurotransmission in mice

Ursolic acid enhances pentobarbital-induced sleeping behaviors via GABAergic neurotransmission in mice

True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence

Antioxidant Activity of Different Solvent Fractions from Prunella vulgaris var. lilacina

Contact Info

Product

Resources

About